Biocept, Inc.
BIOC · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | -$0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -57.8% | 123% | 396.7% | – |
| Gross Profit | -$0 | $0 | $0 | -$0 |
| % Margin | -10% | 38.3% | 22.3% | -98.6% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -117.3% | -3.9% | -52.7% | -417.1% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -124.1% | -4.6% | -62.1% | -445.2% |
| EPS Diluted | -56.78 | -5.73 | -43.16 | -357.41 |
| % Growth | -890.9% | 86.7% | 87.9% | – |
| Operating Cash Flow | -$0 | $0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | $0 | -$0 | -$0 |